Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
76.99
+0.54 (0.71%)
Aug 12, 2026, 9:10 AM EDT - Market open
Cytokinetics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 255.27 | 122.52 | 94.86 | 113.02 | 65.58 | 112.67 |
Short-Term Investments | 910.42 | 759.7 | 981.16 | 501.8 | 717 | 358.97 |
Cash & Short-Term Investments | 1,166 | 882.22 | 1,076 | 614.82 | 782.58 | 471.64 |
Cash Growth | 35.84% | -18.01% | 75.01% | -21.44% | 65.93% | 1.63% |
Accounts Receivable | 24.43 | 17.76 | 16.65 | 1.28 | 0.15 | 51.82 |
Inventory | 0.38 | - | - | - | - | - |
Other Current Assets | 17.99 | 16.99 | 15.28 | 11.94 | 12.46 | 12.22 |
Total Current Assets | 1,208 | 916.98 | 1,108 | 628.05 | 795.19 | 535.67 |
Net Property, Plant & Equipment | 151.81 | 155.17 | 140.97 | 147.74 | 163.19 | 146.41 |
Long-Term Investments | 538.32 | 335.05 | 145.06 | 40.53 | 46.71 | 152.05 |
Other Long-Term Assets | 25.94 | 17.34 | 7.71 | 8 | 9.69 | 7.19 |
Total Assets | 1,925 | 1,425 | 1,402 | 824.32 | 1,015 | 841.32 |
Accounts Payable | 20.51 | 22.34 | 20.37 | 21.51 | 25.61 | 21.09 |
Accrued Expenses | 76.86 | 83.28 | 55.32 | 42.64 | 44.1 | 34.37 |
Current Portion of Long-Term Debt | 27.36 | 41.18 | 11.52 | 10.08 | 0.96 | - |
Current Portion of Leases | 21.04 | 19.11 | 18.98 | 17.89 | 12.83 | 14.86 |
Unearned Revenue | 1.65 | 1.61 | 52.37 | - | - | - |
Other Current Liabilities | 34 | 34.93 | 21.11 | 10.56 | 1.12 | 1.54 |
Total Current Liabilities | 181.43 | 202.45 | 179.67 | 102.68 | 84.62 | 71.86 |
Long-Term Debt | 1,120 | 1,116 | 645.6 | 607.37 | 609.62 | 142.84 |
Long-Term Leases | 102.43 | 107.97 | 112.58 | 120.43 | 126.9 | 112.23 |
Other Long-Term Liabilities | 694.45 | 657.76 | 599.19 | 380.16 | 301.55 | 270.53 |
Total Long-Term Liabilities | 1,917 | 1,882 | 1,357 | 1,108 | 1,038 | 525.6 |
Total Liabilities | 2,098 | 2,084 | 1,537 | 1,211 | 1,123 | 597.46 |
Common Stock | 0.14 | 0.12 | 0.12 | 0.1 | 0.09 | 0.08 |
Additional Paid-in Capital | 3,722 | 2,826 | 2,564 | 1,726 | 1,482 | 1,452 |
Accumulated Other Comprehensive Income | -3.83 | 0.63 | 2.4 | -0.01 | -3.59 | -0.87 |
Retained Earnings | -3,892 | -3,487 | -2,702 | -2,112 | -1,586 | -1,208 |
Shareholders' Equity | -173.49 | -659.63 | -135.37 | -386.32 | -107.9 | 243.86 |
Total Liabilities & Equity | 1,925 | 1,425 | 1,402 | 824.32 | 1,015 | 841.32 |
Total Debt | 1,271 | 1,284 | 788.68 | 755.77 | 750.3 | 269.93 |
Net Cash (Debt) | -104.87 | -402.02 | 287.34 | -140.95 | 32.28 | 201.71 |
Net Cash Growth | - | - | - | - | -84.00% | -37.96% |
Net Cash Per Share | -0.84 | -3.35 | 2.57 | -1.46 | 0.36 | 2.62 |
Book Value | -173.49 | -659.63 | -135.37 | -386.32 | -107.9 | 243.86 |
Book Value Per Share | -1.39 | -5.49 | -1.21 | -4.00 | -1.20 | 3.17 |
Tangible Book Value | -173.49 | -659.63 | -135.37 | -386.32 | -107.9 | 243.86 |
Tangible Book Value Per Share | -1.39 | -5.49 | -1.21 | -4.00 | -1.20 | 3.17 |